Pyxis Oncology Business Summary

Pyxis Oncology, Inc. (PYXS) is a clinical-stage biotechnology company that generates revenue primarily through strategic collaborations and licensing agreements with industry leaders such as Pfizer and LegoChem Biosciences. The company operates through two primary business segments: Antibody-Drug Conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies. Its lead clinical candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is a first-in-concept ADC targeting the EDB+FN protein in the tumor microenvironment, currently undergoing Phase 1/2 trials for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors. Pyxis competes directly with small-cap oncology firms such as Protara Therapeutics, Aclaris Therapeutics, Aura Biosciences, and Puma Biotechnology, positioning itself as a high-innovation specialist focusing on stroma-targeting mechanisms to overcome treatment resistance. The company was founded by a distinguished group including Shaan Gandhi, Thomas Gajewski, David Steinberg, and Chairman John Flavin. As of February 2026, the leadership team is headed by Interim CEO Thomas Civik, a veteran executive who previously served as CEO of Five Prime Therapeutics (acquired by Amgen for $1.9 billion) and Chief Commercial Officer at Foundation Medicine. The technical and financial functions are led by Interim CTO Balu Balasubramanian, Ph.D., and Principal Financial Officer Jitendra Wadhane. Pyxis is backed by a blue-chip roster of institutional investors, including RTW Investments, RA Capital Management, and Leaps by Bayer, with a Board of Directors featuring notable industry figures such as Michael A. Metzger and Dr. Freda Lewis-Hall.